Please login to the form below

Not currently logged in
Email:
Password:

imlygic

This page shows the latest imlygic news and features for those working in and with pharma, biotech and healthcare.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

Latest news

  • NICE turns down CDF drug Adcetris in draft guidance NICE turns down CDF drug Adcetris in draft guidance

    Gives green light to Imlygic. Meanwhile, Amgen's melanoma therapy Imlygic will be made available to NHS patients in England and Wales after a change of heart by NICE. ... Imlygic (talimogene laherparepvec) was turned down by NICE in earlier guidance,

  • NICE swayed by extra data on Amgen's Imlygic NICE swayed by extra data on Amgen's Imlygic

    NICE swayed by extra data on Amgen's Imlygic. Cost effectiveness watchdog backs immunotherapy in final draft guidance. ... NICE has recommended Amgen's advanced melanoma treatment Imlygic (talimongene laherparepvec) in final draft guidance, reversing an

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Imlygic is a genetically modified live herpes virus used to treat melanoma

  • Amgen buys back product rights from GSK Amgen buys back product rights from GSK

    review in Europe, as well as oncolytic virus therapy Imlygic (talimogene laherparepvec), approved in the US in October.

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    The FDA has approved Amgen's Imlygic for melanoma, the first oncolytic virus therapy to get a green light in the US. ... Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and

More from news
Approximately 5 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics